Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy & Targeted Therapies, and Others), Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026

February 2020 | 261 pages | ID: U22D36514C34EN
Allied Market Research

Abstracts

The global uveitis treatment market was valued at $478 million in 2018, and is projected to reach $687 million by 2026, registering a CAGR of 4.6% from 2019 to 2026.

Uveitis is the inflammation of the middle layer of tissue in the eye wall uvea that consists of the iris, choroid, and ciliary body. Different forms of drug such as cycloplegic agents, anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others are used in the treatment of uveitis. Different types of uveitis include anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. The most common type of uveitis is an inflammation of iris called iritis or anterior uveitis. Uveitis can be serious, leading to permanent vision loss.

The uveitis treatment market is expected to experience significant growth during the forecast period, owing to increase in prevalence of uveitis, rise in popularity of advanced therapeutics, and wide availability of drugs. In addition, early detection of the disease and surge in R&D activities to developed ideal therapeutics further fuel the market growth. However, unknown etiology and pathophysiology of uveitis and adverse effects associated with the treatment therapeutics may hamper the market growth.

The global uveitis treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, the market is classified into anti-inflammatory, antimicrobial drugs, immunotherapy & targeted therapies, and others. Disease type such as anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are covered in the report. According to distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Drug Class

• Anti-inflammatory
• Antimicrobial Drugs
• Immunotherapy & Targeted Therapies
• Others

Disease Type

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Panuveitis

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa
• Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

• AbbVie Inc.
• Alimera Sciences, Inc.
• Allergan Plc.
• Amgen Inc.
• Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Mylan N.V.
• Novartis AG
• Santen Pharmaceutical Co., Ltd.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

• Aldeyra Therapeutics, Inc.
• Aciont Inc.

Contents

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
  1.3.1. List of key players profiled in the report
1.4. Research methodology
  1.4.1. Secondary research
  1.4.2. Primary research
  1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. Key findings
  2.2.1. Top investment pockets
  2.2.2. Market player positioning, 2018
2.3. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key forces shaping uveitis treatment industry/market
  3.2.1. Moderate power of suppliers
  3.2.2. High threat of new entrants
  3.2.3. High threat of substitution
  3.2.4. Moderate competitive rivalry
  3.2.5. Moderate bargaining power of buyers
3.3. Market dynamics
  3.3.1. Drivers
    3.3.1.1. Increase in prevalence of uveitis
    3.3.1.2. Potential drugs in pipeline
    3.3.1.3. Surge in healthcare expenditure worldwide
  3.3.2. Restraint
    3.3.2.1. Unknown etiology of uveitis
  3.3.3. Opportunities
    3.3.3.1. Growth opportunities in emerging markets
    3.3.3.2. Higher number of unmet needs for treatment of uveitis
  3.3.4. Impact analysis

CHAPTER 4: UVEITIS TREATMENT MARKET, BY DRUG CLASS

4.1. Overview
  4.1.1. Market size and forecast
4.2. Anti-inflammatory
  4.2.1. Key market trends and opportunities
  4.2.2. Market size and forecast, by region
  4.2.3. Market analysis, by country
4.3. Antimicrobial drugs
  4.3.1. Key market trends and opportunities
  4.3.2. Market size and forecast, by region
  4.3.3. Market analysis, by country
4.4. Immunotherapy & targeted therapies
  4.4.1. Key market trends and opportunities
  4.4.2. Market size and forecast, by region
  4.4.3. Market analysis, by country
4.5. Others
  4.5.1. Key market trends and opportunities
  4.5.2. Market size and forecast, by region
  4.5.3. Market analysis, by country

CHAPTER 5: UVEITIS TREATMENT MARKET, BY DISEASE TYPE

5.1. Overview
  5.1.1. Market size and forecast
5.2. Anterior uveitis
  5.2.1. Market size and forecast
  5.2.2. Market analysis, by country
5.3. Posterior uveitis
  5.3.1. Market size and forecast
  5.3.2. Market analysis, by country
5.4. Intermediate uveitis
  5.4.1. Market size and forecast
  5.4.2. Market analysis, by country
5.5. Panuveitis
  5.5.1. Market size and forecast
  5.5.2. Market analysis, by country

CHAPTER 6: UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
  6.1.1. Market size and forecast
6.2. Hospitals pharmacies
  6.2.1. Market size and forecast
  6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
  6.3.1. Market size and forecast
  6.3.2. Market analysis, by country
6.4.
6.5. Online pharmacies
  6.5.1. Market size and forecast
  6.5.2. Market analysis, by country

CHAPTER 7: UVEITIS TREATMENT MARKET, BY REGION

7.1. Overview
  7.1.1. Market size and forecast
7.2. North America
  7.2.1. Key market trends, growth factors, and opportunities
  7.2.2. Market size and forecast, by country
    7.2.2.1. U.S.
      7.2.2.1.1. U.S. uveitis treatment market, by drug class
      7.2.2.1.2. U.S. uveitis treatment market, by disease type
      7.2.2.1.3. U.S. uveitis treatment market, by distribution channel
    7.2.2.2. Canada
      7.2.2.2.1. Canada uveitis treatment market, by drug class
      7.2.2.2.2. Canada uveitis treatment market, by disease type
      7.2.2.2.3. Canada uveitis treatment market, by distribution channel
    7.2.2.3. Mexico
      7.2.2.3.1. Mexico uveitis treatment market, by drug class
      7.2.2.3.2. Mexico uveitis treatment market, by disease type
      7.2.2.3.3. Mexico uveitis treatment market, by distribution channel
  7.2.3. North America market size and forecast, by drug class
  7.2.4. North America uveitis treatment market, by disease type
  7.2.5. North America uveitis treatment market, by distribution channel
7.3. Europe
  7.3.1. Key market trends, growth factors, and opportunities
  7.3.2. Market size and forecast, by country
    7.3.2.1. Germany
      7.3.2.1.1. Germany uveitis treatment market, by drug class
      7.3.2.1.2. Germany uveitis treatment market, by disease type
      7.3.2.1.3. Germany uveitis treatment market, by distribution channel
    7.3.2.2. France
      7.3.2.2.1. France uveitis treatment market, by drug class
      7.3.2.2.2. France uveitis treatment market, by disease type
      7.3.2.2.3. France uveitis treatment market, by distribution channel
    7.3.2.3. UK
      7.3.2.3.1. UK uveitis treatment market, by drug class
      7.3.2.3.2. UK uveitis treatment market, by disease type
      7.3.2.3.3. UK uveitis treatment market, by distribution channel
    7.3.2.5. Italy
      7.3.2.5.1. Italy uveitis treatment market, by drug class
      7.3.2.5.2. Italy uveitis treatment market, by disease type
      7.3.2.5.3. Italy uveitis treatment market, by distribution channel
    7.3.2.6. Spain
      7.3.2.6.1. Spain uveitis treatment market, by drug class
      7.3.2.6.2. Spain uveitis treatment market, by disease type
      7.3.2.6.3. Spain uveitis treatment market, by distribution channel
    7.3.2.7. Rest of Europe
      7.3.2.7.1. Rest of Europe uveitis treatment market, by drug class
      7.3.2.7.2. Rest of Europe uveitis treatment market, by disease type
      7.3.2.7.3. Rest of Europe uveitis treatment market, by distribution channel
  7.3.3. Europe market size and forecast, by drug class
  7.3.4. Europe uveitis treatment market, by disease type
  7.3.5. Europe uveitis treatment market, by distribution channel
7.4. Asia-Pacific
  7.4.1. Key market trends, growth factors, and opportunities
  7.4.2. Market size and forecast, by country
    7.4.2.1. Japan
      7.4.2.1.1. Japan uveitis treatment market, by drug class
      7.4.2.1.2. Japan uveitis treatment market, by disease type
      7.4.2.1.3. Japan uveitis treatment market, by distribution channel
    7.4.2.2. China
      7.4.2.2.1. China uveitis treatment market, by drug class
      7.4.2.2.2. China uveitis treatment market, by disease type
      7.4.2.2.3. China uveitis treatment market, by distribution channel
    7.4.2.3. Australia
      7.4.2.3.1. Australia uveitis treatment market, by drug class
      7.4.2.3.2. Australia uveitis treatment market, by disease type
      7.4.2.3.3. Australia uveitis treatment market, by distribution channel
    7.4.2.5. India
      7.4.2.5.1. India uveitis treatment market, by drug class
      7.4.2.5.2. India uveitis treatment market, by disease type
      7.4.2.5.3. India uveitis treatment market, by distribution channel
    7.4.2.6. South Korea
      7.4.2.6.1. South Korea uveitis treatment market, by drug class
      7.4.2.6.2. South Korea uveitis treatment market, by disease type
      7.4.2.6.3. South Korea uveitis treatment market, by distribution channel
    7.4.2.7. Rest of Asia-Pacific
      7.4.2.7.1. Rest of Asia-Pacific uveitis treatment market, by drug class
      7.4.2.7.2. Rest of Asia-Pacific uveitis treatment market, by disease type
      7.4.2.7.3. Rest of Asia-Pacific uveitis treatment market, by distribution channel
  7.4.3. Asia-Pacific market size and forecast, by drug class
  7.4.4. Asia-Pacific uveitis treatment market, by disease type
  7.4.5. Asia-Pacific uveitis treatment market, by distribution channel
7.5. LAMEA
  7.5.1. Key market trends, growth factors, and opportunities
  7.5.2. Market size and forecast, by country
    7.5.2.1. Brazil
      7.5.2.1.1. Brazil uveitis treatment market, by drug class
      7.5.2.1.2. Brazil uveitis treatment market, by disease type
      7.5.2.1.3. Brazil uveitis treatment market, by distribution channel
    7.5.2.3. Saudi Arabia
      7.5.2.3.1. Saudi Arabia uveitis treatment market, by drug class
      7.5.2.3.2. Saudi Arabia uveitis treatment market, by disease type
      7.5.2.3.3. Saudi Arabia uveitis treatment market, by distribution channel
    7.5.2.4. South Africa
      7.5.2.4.1. South Africa uveitis treatment market, by drug class
      7.5.2.4.2. South Africa uveitis treatment market, by disease type
      7.5.2.4.3. South Africa uveitis treatment market, by distribution channel
    7.5.2.5. Rest of LAMEA
      7.5.2.5.1. Rest of LAMEA uveitis treatment market, by drug class
      7.5.2.5.2. Rest of LAMEA uveitis treatment market, by disease type
      7.5.2.5.3. Rest of LAMEA uveitis treatment market, by distribution channel
  7.5.3. LAMEA market size and forecast, by drug class
  7.5.4. LAMEA uveitis treatment market, by disease type
  7.5.5. LAMEA uveitis treatment market, by distribution channel

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.
  8.1.1. Company overview
  8.1.2. Company snapshot
  8.1.3. Operating business segments
  8.1.4. Product portfolio
  8.1.5. Business performance
8.2. Alimera Sciences, Inc.
  8.2.1. Company overview
  8.2.2. Company snapshot
  8.2.3. Operating business segments
  8.2.4. Product portfolio
  8.2.5. Business performance
  8.2.6. Key strategic moves and developments
8.3. Allergan Plc.
  8.3.1. Company overview
  8.3.2. Company snapshot
  8.3.3. Operating business segments
  8.3.4. Product portfolio
  8.3.5. Business performance
8.4. Amgen Inc.
  8.4.1. Company overview
  8.4.2. Company snapshot
  8.4.3.
  8.4.4. Operating business segments
  8.4.5. Product portfolio
  8.4.6. Business performance
  8.4.7. Key strategic moves and developments
8.5. Bausch Health Companies Inc. (Bausch & Lomb Incorporated)
  8.5.1. Company overview
  8.5.2. Company snapshot
  8.5.3. Operating business segments
  8.5.4. Product portfolio
  8.5.5. Business performance
8.6. Clearside Biomedical, Inc.
  8.6.1. Company overview
  8.6.2. Company snapshot
  8.6.3. Product Portfolio
  8.6.4. Business performance
8.7. EyePoint Pharmaceuticals, Inc.
  8.7.1. Company overview
  8.7.2. Company snapshot
  8.7.3. Product Portfolio
  8.7.4. Key strategic moves and developments
8.8. Mylan N.V.
  8.8.1. Company overview
  8.8.2. Company snapshot
  8.8.3. Operating business segments
  8.8.4. Product portfolio
  8.8.5. Business performance
  8.8.6. Key strategic moves and developments
8.9. Novartis AG
  8.9.1. Company overview
  8.9.2. Company snapshot
  8.9.3. Operating business segments
  8.9.4. Product portfolio
  8.9.5. Business performance
  8.9.6. Key strategic moves and developments
8.10. Santen Pharmaceutical Co., Ltd.
  8.10.1. Company overview
  8.10.2. Company snapshot
  8.10.3. Product portfolio
  8.10.4. Business performance

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026 ($MILLION)
TABLE 02. ANTI-INFLAMMATORY MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ANTIMICROBIAL DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. IMMUNOTHERAPY AND TARGETED THERAPIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026 ($MILLION)
TABLE 07. ANTERIOR UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. POSTERIOR UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. INTERMEDIATE UVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. PANUVEITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. GLOBAL UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 12. UVEITIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 13. UVEITIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 14. UVEITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 15. UVEITIS TREATMENT MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 16. NORTH AMERICA UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17. U.S. UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 18. U.S. UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 19. U.S. UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 20. CANADA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 21. CANADA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 22. CANADA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 23. MEXICO UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 24. MEXICO UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 25. MEXICO UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 26. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 27. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 28. NORTH AMERICA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 29. EUROPE UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 30. GERMANY UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 31. GERMANY UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 32. GERMANY UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 33. FRANCE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 34. FRANCE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 35. FRANCE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 36. UK UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 37. UK UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 38. UK UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 39. ITALY UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 40. ITALY UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 41. ITALY UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 42. SPAIN UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 43. SPAIN UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 44. SPAIN UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 45. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 46. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 47. REST OF EUROPE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 48. EUROPE UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 49. EUROPE UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 50. EUROPE UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 51. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 52. JAPAN UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 53. JAPAN UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 54. JAPAN UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 55. CHINA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 56. CHINA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 57. CHINA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 58. AUSTRALIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 59. AUSTRALIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 60. AUSTRALIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 61. INDIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 62. INDIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 63. INDIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 64. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 65. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 66. SOUTH KOREA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 68. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 69. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 70. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 71. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 72. ASIA-PACIFIC UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 73. LAMEA UVEITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 74. BRAZIL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 75. BRAZIL UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 76. BRAZIL UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 77. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 78. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 79. SAUDI ARABIA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 80. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 81. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 82. SOUTH AFRICA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 83. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 84. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 85. REST OF LAMEA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 86. LAMEA UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2018–2026
TABLE 87. LAMEA UVEITIS TREATMENT MARKET, BY DISEASE TYPE, 2018–2026
TABLE 88. LAMEA UVEITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 89. ABBVIE INC: COMPANY SNAPSHOT
TABLE 90. ABBVIE INC: OPERATING SEGMENTS
TABLE 91. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 92. ALIMERA: COMPANY SNAPSHOT
TABLE 93. ALIMERA: OPERATING SEGMENTS
TABLE 94. ALIMERA: PRODUCT PORTFOLIO
TABLE 95. ALLERGAN: COMPANY SNAPSHOT
TABLE 96. ALLERGAN: OPERATING SEGMENTS
TABLE 97. ALLERGAN: PRODUCT PORTFOLIO
TABLE 98. AMGEN: COMPANY SNAPSHOT
TABLE 99. AMGEN: PRODUCT SEGMENT
TABLE 100. AMGEN: PRODUCT PORTFOLIO
TABLE 101. BAUSCH & LOMB: COMPANY SNAPSHOT
TABLE 102. BAUSCH & LOMB: OPERATING SEGMENTS
TABLE 103. BAUSCH & LOMB: PRODUCT PORTFOLIO
TABLE 104. CLEARSIDE: COMPANY SNAPSHOT
TABLE 105. EYEPOINT: COMPANY SNAPSHOT
TABLE 106. EYEPOINT: PRODUCT PORTFOLIO
TABLE 107. MYLAN: COMPANY SNAPSHOT
TABLE 108. MYLAN: OPERATING SEGMENTS
TABLE 109. MYLAN: PRODUCT PORTFOLIO
TABLE 110. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 111. NOVARTIS: OPERATING SEGMENTS
TABLE 112. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 113. SANTEN: COMPANY SNAPSHOT
TABLE 114. SANTEN: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01. TOP INVESTMENT POCKETS
FIGURE 02. MARKET PLAYER POSITIONING, 2018
FIGURE 03. GLOBAL UVEITIS TREATMENT MARKET SEGMENTATION
FIGURE 04. IMPACT ANALYSIS
FIGURE 05. COMPARATIVE ANALYSIS OF ANTI-INFLAMMATORY MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 06. COMPARATIVE ANALYSIS OF ANTIMICROBIAL DRUGS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 07. COMPARATIVE ANALYSIS OF IMMUNOTHERAPY AND TARGETED THERAPIES MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF OTHERS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF ANTERIOR UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF POSTERIOR UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF INTERMEDIATE UVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF PANUVEITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF UVEITIS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 16. U.S. UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 17. CANADA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 18. MEXICO UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. GERMANY UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. FRANCE UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. UK UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. ITALY UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. SPAIN UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. REST OF EUROPE UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. JAPAN UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. CHINA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. AUSTRALIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. INDIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. SOUTH KOREA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. BRAZIL UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. SAUDI ARABIA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 33. SOUTH AFRICA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 34. REST OF LAMEA UVEITIS TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 35. ABBVIE INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 37. ABBVIE INC: REVENUE SHARE BY REGION, 2018(%)
FIGURE 38. ALIMERA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. ALIMERA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. ALLERGAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. ALLERGAN: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 42. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. BAUSCH & LOMB: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. BAUSCH & LOMB: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. BAUSCH & LOMB: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 47. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 49. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 51. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 52. SANTEN: REVENUE, 2016–2018 ($MILLION)
FIGURE 53. SANTEN: REVENUE SHARE BY REGION, 2018 (%)